Todd, Kirsten L. http://orcid.org/0000-0002-3903-166X
Lai, Junyun http://orcid.org/0000-0001-5884-2786
Sek, Kevin http://orcid.org/0000-0003-4634-7600
Huang, Yu-Kuan http://orcid.org/0000-0003-2262-7069
Newman, Dane M.
Derrick, Emily B. http://orcid.org/0000-0001-7191-3948
Koay, Hui-Fern http://orcid.org/0000-0002-3236-9609
Nguyen, Dat
Hoang, Thang X.
Petley, Emma V.
Chan, Cheok Weng
Munoz, Isabelle http://orcid.org/0000-0001-6510-5696
House, Imran G.
Lee, Joel N.
Kim, Joelle S.
Li, Jasmine
Tong, Junming
N. de Menezes, Maria
Scheffler, Christina M. http://orcid.org/0000-0003-3731-6204
Yap, Kah Min
Chen, Amanda X. Y.
Dunbar, Phoebe A.
Haugen, Brandon
Parish, Ian A. http://orcid.org/0000-0003-3528-478X
Johnstone, Ricky W. http://orcid.org/0000-0001-7053-9237
Darcy, Phillip K. http://orcid.org/0000-0002-5303-9561
Beavis, Paul A. http://orcid.org/0000-0002-2116-013X
Funding for this research was provided by:
Victorian Cancer Agency (MCRF20011)
National Breast Cancer Foundation (ECF-17-005)
Article History
Received: 11 April 2023
Accepted: 20 October 2023
First Online: 1 November 2023
Competing interests
: P.A.B. declares the following conflicts: research funding from AstraZeneca, Bioardis, Bristol-Myers-Squibb and Gilead Sciences. P.K.D. declares the following conflicts: research funding from Myeloid Therapeutics, Prescient Therapeutics, Bristol-Myers-Squibb and Juno Therapeutics. I.A.P. declares the following conflicts: research funding from Bristol-Myers-Squibb and Astrazeneca. The Johnstone Lab receives research support from Roche, BMS, AstraZeneca and MecRx. R.W.J. is a scientific consultant and shareholder in MecRx. The remaining authors declare no competing interests.